On World Diabetes Day, it's worth taking a look back at the last 10.5 months in the diabetes technology space.

Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that management will present at three upcoming ...

Insulet’s Omnipod 5 automated insulin delivery (AID) system has multiple avenues to expand as it has revolutionized the way patients treat their diabetes, including the new indication for Type 2 ...

Kamen and Sequel Medtech CEO Alan Lotvin say they are offering greater precision in insulin delivery with new pump technology ...

Insulet (Nasdaq:PODD) shares ticked up today on third-quarter results that came in well ahead of the consensus forecast.

Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod brand of products, today announced that management will present at three upcoming ...

Insulet saw strong insulin pump adoption among new users with Type 2 diabetes following its recent FDA clearance, while ...

The company now expects its annual 2024 revenue to grow between 20% and 21%, up from its previous forecast of 16% to 19% ...

Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM – Get Free Report) have earned an average recommendation of “Moderate Buy” from the eighteen research firms that are presently covering the stock, ...

Insulet ( (PODD) ) has released its Q3 earnings. Here is a breakdown of the information Insulet presented to its investors. Insulet ...

Reports Q3 revenue $543.9M, consensus $518.26M. “We continue to achieve significant milestones and robust revenue growth,” said Jim ...

CNW/ - Ypsomed and CamDiab are pleased to announce the approval of mylife YpsoPump insulin pump and CamAPS FX hybrid closed-loop algorithm by Health Canada. This approval represents an important step ...